BiotechTube

SAL003 140 mg + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemias

Conditions

Hyperlipidemias

Trial Timeline

Oct 23, 2023 → May 8, 2025

NCT ID
NCT07295418

About SAL003 140 mg + Placebo

SAL003 140 mg + Placebo is a phase 3 stage product being developed by Shenzhen Salubris Pharmaceuticals for Hyperlipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT07295418. Target conditions include Hyperlipidemias.

What happened to similar drugs?

2 of 4 similar drugs in Hyperlipidemias were approved

Approved (2) Terminated (0) Active (2)
✅Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
✅atorvastatin + atorvastatin + atorvastatinPfizerApproved
🔄SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
🔄Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07253584Phase 3Completed
NCT07295418Phase 3Completed

Competing Products

5 competing products in Hyperlipidemias

See all competitors
ProductCompanyStageHype Score
Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
39
atorvastatin + atorvastatin + atorvastatinPfizerApproved
43
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40
SLN360 + PlaceboMedpacePhase 1
26
Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3
34